Advertisement
Research Article

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

  • Daniel B Costa,

    Affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Balázs Halmos,

    Affiliation: University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States of America

    X
  • Amit Kumar,

    Affiliation: Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, United States of America

    X
  • Susan T Schumer,

    Affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Mark S Huberman,

    Affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Titus J Boggon,

    Affiliation: Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, United States of America

    X
  • Daniel G Tenen,

    Affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Susumu Kobayashi mail

    To whom correspondence should be addressed. E-mail: skobayas@bidmc.harvard.edu

    Affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Published: October 30, 2007
  • DOI: 10.1371/journal.pmed.0040315

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.